Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Other Non-Current Liabilities (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Other Non-Current Liabilities data on record, last reported at $47.8 million in Q1 2024.

  • For Q1 2024, Other Non-Current Liabilities rose 37.95% year-over-year to $47.8 million; the TTM value through Mar 2024 reached $47.8 million, up 37.95%, while the annual FY2024 figure was $47.9 million, 36.99% up from the prior year.
  • Other Non-Current Liabilities reached $47.8 million in Q1 2024 per RDY's latest filing, up from $34.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $47.8 million in Q1 2024 and bottomed at $32.1 million in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $37.1 million, with a median of $34.6 million recorded in 2023.
  • Peak YoY movement for Other Non-Current Liabilities: fell 17.04% in 2021, then skyrocketed 37.95% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $38.7 million in 2020, then fell by 17.04% to $32.1 million in 2021, then rose by 0.24% to $32.2 million in 2022, then rose by 7.56% to $34.6 million in 2023, then soared by 37.95% to $47.8 million in 2024.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $47.8 million in Q1 2024, $34.6 million in Q1 2023, and $32.2 million in Q1 2022.